Qingfan Yang

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

PI(4,5)P2 alleviates colitis by inhibiting intestinal epithelial cell pyroptosis through NNMT-mediated RBP4 m6A modification.

PI(4,5)P2 alleviates colitis by inhibiting intestinal epithelial cell pyroptosis through NNMT-mediated RBP4 m6A modification.

Journal: Cell death & disease

Published: May 22, 2024

Identification of hub programmed cell death-related genes and immune infiltration in Crohn's disease using bioinformatics.

Identification of hub programmed cell death-related genes and immune infiltration in Crohn's disease using bioinformatics.

Journal: Frontiers in genetics

Published: April 29, 2024

Comparison of clinical and endoscopic efficacy between vedolizumab and infliximab in bio-naïve patients with ulcerative colitis: a multicenter, real-world study.

Comparison of clinical and endoscopic efficacy between vedolizumab and infliximab in bio-naïve patients with ulcerative colitis: a multicenter, real-world study.

Journal: Therapeutic advances in gastroenterology

Published: March 21, 2024

Intestinal mRNA expression profiles associated with mucosal healing in ustekinumab-treated Crohn's disease patients: bioinformatics analysis and prospective cohort validation.

Intestinal mRNA expression profiles associated with mucosal healing in ustekinumab-treated Crohn's disease patients: bioinformatics analysis and prospective cohort validation.

Journal: Journal of translational medicine

Published: March 20, 2024

Comparative Effectiveness of Infliximab vs Ustekinumab for Endoscopic and Transmural Remission in Biologic Naïve Crohn's Disease.

Comparative Effectiveness of Infliximab vs Ustekinumab for Endoscopic and Transmural Remission in Biologic Naïve Crohn's Disease.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: February 27, 2024

Exclusive Enteral Nutrition Orchestrates Immunological Balances as Early as Week 4 in Adult Patients of Crohn's Disease: A Pilot, Open-Lable Study.

Exclusive Enteral Nutrition Orchestrates Immunological Balances as Early as Week 4 in Adult Patients of Crohn's Disease: A Pilot, Open-Lable Study.

Journal: Nutrients

Published: October 14, 2023

Changes in the clinical course and prognosis of ulcerative colitis in Chinese populations: a retrospective cohort study.

Changes in the clinical course and prognosis of ulcerative colitis in Chinese populations: a retrospective cohort study.

Journal: Intestinal research

Published: August 21, 2023

A novel location classification system for Crohn's disease based on small bowel involvement: a better predictor of disease progression.

A novel location classification system for Crohn's disease based on small bowel involvement: a better predictor of disease progression.

Journal: Gastroenterology report

Published: August 09, 2023

Amino acid-based enteral nutrition is effective for pediatric Crohn's disease: a multicenter prospective study.

Amino acid-based enteral nutrition is effective for pediatric Crohn's disease: a multicenter prospective study.

Journal: Gastroenterology report

Published: July 09, 2023

Lipidomics reveals significant alterations associated with exclusive enteral nutrition treatment in adult patients with active Crohn's disease.

Lipidomics reveals significant alterations associated with exclusive enteral nutrition treatment in adult patients with active Crohn's disease.

Journal: Annals of translational medicine

Published: August 10, 2022

Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease.

Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease.

Journal: Alimentary pharmacology & therapeutics

Published: March 23, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026